Ayesha Azraa, Wallace Ryan T, Mai Anthony P, Simpson Rachel G, Chaya Craig J
University of Utah School of Medicine, USA.
Baylor College of Medicine Department of Ophthalmology, USA.
Am J Ophthalmol Case Rep. 2023 Jan 25;30:101806. doi: 10.1016/j.ajoc.2023.101806. eCollection 2023 Jun.
To report the observation of iris atrophy with the use of Dexycu in cataract surgery and describe a possible mechanism for this complication.
Between 2020 and 2021, 2 patients underwent cataract surgery procedures with the use of Dexycu and experienced iris atrophy. The first case of iris atrophy was discovered by 6-month follow-up and the second case by 2-month follow-up. The timing and nature of this complication possibly represent more than steroid-induced hypopigmentation.
This publication adds further evidence of iris atrophy and a proposed mechanism associated with the use of Dexycu. Surgeons should be aware of this complication, especially when operating on eyes with dark irides.
报告在白内障手术中使用德西库（Dexycu）时观察到的虹膜萎缩情况，并描述这种并发症的一种可能机制。
在2020年至2021年期间，2例患者在使用德西库进行白内障手术过程中出现了虹膜萎缩。第一例虹膜萎缩在6个月随访时发现，第二例在2个月随访时发现。这种并发症的发生时间和性质可能不仅仅是类固醇诱导的色素减退。
本出版物进一步证明了虹膜萎缩以及与使用德西库相关的一种推测机制。外科医生应意识到这种并发症，尤其是在对深虹膜的眼睛进行手术时。
